Stock Analysis
- South Korea
- /
- Biotech
- /
- KOSDAQ:A086900
Three Growth Companies With High Insider Ownership On KRX
Reviewed by Simply Wall St
Over the last 7 days, the South Korean market has risen 1.9%, driven by gains in the Financials and Information Technology sectors of 5.7% and 1.4%, respectively. In light of this positive momentum and a forecasted annual earnings growth of 29%, identifying growth companies with high insider ownership can be particularly advantageous for investors seeking strong alignment between management interests and shareholder value.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.5% | 35.6% |
Bioneer (KOSDAQ:A064550) | 17.5% | 89.7% |
Global Tax Free (KOSDAQ:A204620) | 21.4% | 78.5% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.8% | 62.1% |
Oscotec (KOSDAQ:A039200) | 26.3% | 114.7% |
Park Systems (KOSDAQ:A140860) | 33% | 37.5% |
Vuno (KOSDAQ:A338220) | 19.5% | 110.9% |
HANA Micron (KOSDAQ:A067310) | 20.2% | 97.4% |
UTI (KOSDAQ:A179900) | 33.1% | 122.7% |
Techwing (KOSDAQ:A089030) | 18.7% | 77.8% |
Let's explore several standout options from the results in the screener.
Medy-Tox (KOSDAQ:A086900)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medy-Tox Inc. is a South Korean biopharmaceutical company with a market cap of ₩1.44 trillion.
Operations: Medy-Tox generates revenue primarily from its biotechnology segment, amounting to ₩233.03 billion.
Insider Ownership: 19.8%
Revenue Growth Forecast: 12.4% p.a.
Medy-Tox, a growth company with high insider ownership in South Korea, is trading at 55.8% below its estimated fair value. Although its revenue is forecast to grow at 12.4% per year, slower than the desired 20%, earnings are expected to grow significantly at 63.91% annually over the next three years, outpacing the market's average of 28.5%. However, profit margins have declined from 18.5% last year to just 0.8%, and the share price has been highly volatile recently.
- Unlock comprehensive insights into our analysis of Medy-Tox stock in this growth report.
- In light of our recent valuation report, it seems possible that Medy-Tox is trading behind its estimated value.
SungEel HiTech (KOSDAQ:A365340)
Simply Wall St Growth Rating: ★★★★★☆
Overview: SungEel HiTech Co., Ltd. operates as a secondary battery recycling company in South Korea, with a market cap of ₩673.50 billion.
Operations: The company's revenue segments include ₩232.20 billion from Secondary Battery Raw Material Manufacturing and a consolidation adjustment of -₩32.71 million.
Insider Ownership: 38%
Revenue Growth Forecast: 35% p.a.
SungEel HiTech's earnings are forecast to grow 49.17% annually, significantly outpacing the South Korean market's average of 28.5%. Revenue is expected to increase by 35% per year, faster than the market's 10.4%. However, profit margins have declined from 12.5% last year to 3.4%, and its return on equity is projected to be low at 7.6%. Additionally, debt coverage through operating cash flow remains a concern for the company’s financial health.
- Navigate through the intricacies of SungEel HiTech with our comprehensive analyst estimates report here.
- According our valuation report, there's an indication that SungEel HiTech's share price might be on the expensive side.
Foosung (KOSE:A093370)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Foosung Co., Ltd., along with its subsidiaries, manufactures and sells chemical products for various industries including automotive, iron and steel, semiconductor, construction, and environmental sectors in South Korea, with a market cap of ₩705.74 billion.
Operations: The company's revenue segments include Chemical Equipment (₩178.79 million) and Fluorine Compounds (₩318.50 million).
Insider Ownership: 32.9%
Revenue Growth Forecast: 13.8% p.a.
Foosung's revenue is forecast to grow at 13.8% annually, outpacing the South Korean market's 10.4%. The company is expected to become profitable within three years, with earnings projected to grow at 73.65% per year. Recent earnings reports show significant improvement, with Q2 sales reaching KRW 956.59 million and net income turning positive at KRW 14,428.32 million from a loss last year. However, debt coverage remains an issue and shareholders experienced dilution in the past year.
- Delve into the full analysis future growth report here for a deeper understanding of Foosung.
- Upon reviewing our latest valuation report, Foosung's share price might be too optimistic.
Summing It All Up
- Discover the full array of 91 Fast Growing KRX Companies With High Insider Ownership right here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Want To Explore Some Alternatives?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A086900
Medy-Tox
Operates as a biopharmaceutical company in South Korea.